Artiva Biotherapeutics’ (ARTV) “Buy” Rating Reiterated at Needham & Company LLC

Artiva Biotherapeutics (NASDAQ:ARTV)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham & Company LLC in a research report issued on Wednesday,Benzinga reports. They currently have a $23.00 price objective on the stock. Needham & Company LLC’s target price suggests a potential upside of 118.84% from the stock’s previous close.

Other research analysts have also recently issued reports about the company. TD Cowen started coverage on Artiva Biotherapeutics in a research note on Tuesday, August 13th. They set a “buy” rating for the company. Cantor Fitzgerald initiated coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They set an “overweight” rating and a $23.00 price objective for the company. Wedbush restated an “outperform” rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a research note on Friday, August 30th. Finally, Jefferies Financial Group began coverage on shares of Artiva Biotherapeutics in a research note on Tuesday, August 13th. They issued a “buy” rating and a $21.00 price target for the company. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Artiva Biotherapeutics presently has a consensus rating of “Buy” and a consensus target price of $21.25.

Artiva Biotherapeutics Stock Down 10.2 %

NASDAQ ARTV opened at $10.51 on Wednesday. Artiva Biotherapeutics has a one year low of $9.68 and a one year high of $17.31. The company has a 50 day simple moving average of $12.60.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.24). Equities research analysts anticipate that Artiva Biotherapeutics will post -4.6 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets purchased a new stake in Artiva Biotherapeutics during the third quarter worth approximately $42,000. MetLife Investment Management LLC acquired a new stake in Artiva Biotherapeutics during the third quarter worth approximately $135,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $623,000. Finally, Acuta Capital Partners LLC purchased a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $680,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.